In a report released today, Kevin Dede from H.C. Wainwright reiterated a Buy rating on Medical Transcription Billing (MTBC), with a price target of $6. The company’s shares closed yesterday at $5.23, close to its 52-week high of $5.65.
According to TipRanks.com, Dede is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -14.6% and a 31.7% success rate. Dede covers the Consumer Goods sector, focusing on stocks such as Top Image Systems, Microvision, and SuperCom.
Medical Transcription Billing has an analyst consensus of Moderate Buy, with a price target consensus of $6.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.65 and a one-year low of $2.11. Currently, Medical Transcription Billing has an average volume of 145.8K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Medical Transcription Billing Corp. is a healthcare information technology company, which engages in the provision of integrated suite of proprietary web-based solutions. Its products and services include electronic health records, practice management, patient engagement, medical billing, value added, consultancy, medical transcription, and business intelligence. The company was founded by Mahmud Ul Haq on September 28, 2001 and is headquartered in Somerset, NY.
